Bibliographies thématiques / Thyroid cancer, Thyroglobulin

Littérature scientifique sur le sujet « Thyroid cancer, Thyroglobulin »

Auteur : Grafiati
Publié le 10 mars 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Sommaire

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Thyroid cancer, Thyroglobulin ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Thyroid cancer, Thyroglobulin"

1

Silgado, Maria Laura Ricardo, Arnav Kamat, Nazia Sadiq, Gul Bahtiyar et Giovanna Rodriguez. « ODP489 Insular Thyroid Cancer : A Rare Case of Undifferentiated Thyroid Carcinoma ». Journal of the Endocrine Society 6, Supplement_1 (1 novembre 2022) : A769—A770. http://dx.doi.org/10.1210/jendso/bvac150.1589.

Texte intégral
Résumé :
Abstract Introduction Insular thyroid cancer (ITC) is a rare form of thyroid cancer derived from follicular cells. ITC requires a histopathologic diagnosis and has an intermediate morphology between well differentiated thyroid cancers (follicular and papillary) and undifferentiated thyroid cancer (anaplastic). The rate of metastasis and mortality are higher compared with well-differentiated thyroid carcinomas. Case presentation A 74-year-old woman presented for a 1 year history of rapidly progressive neck mass associated with neck pain, limited neck motion, loss of appetite, weight loss, and dysphagia. Past medical history included hypertension, type 2 diabetes, dyslipidemia, and vitamin D deficiency. There was no history of neck radiation or family history of cancer. Physical examination revealed a 10×7 cm neck mass with cervical adenopathy. Vital signs were unremarkable. Laboratory studies showed TSH of 0.71 uIU/mL (0.270-4.200), free T4 of 0.57 ng/dL (0.93-1.70) and thyroglobulins of 213.616 ng/dL (1.6-59.9). Neck CT demonstrated a multilobulated mass in the left thyroid lobe measuring 12×5.2×5.6 cm with tracheal deviation, multiple nodules surrounding the carotids and bone metastasis. Fine needle aspiration showed a mixed pattern of thyroid follicles. An excisional biopsy showed nests and sheets of small uniform cells with scattered abortive follicles and mitosis consistent with ITC. There was no necrosis. The Ki67 index was 10-20%. On immunohistochemical analysis TTF1 and thyroglobulin were positive and P63, calcitonin, and PTH were negative. Tracheostomy and PEG tube placement were required due to mass obstructive effect. Radiation and steroids were initiated before starting lenvatinib. The patient was not a surgical candidate due to tumor extension to the carotids. She ultimately succumbed to the disease after a 45-day hospital course complicated by pneumonia. Discussion ITC is a rare type of thyroid tumor with a mortality rate of 12-75%. The diagnosis is based on histopathology, demonstrating solid nests (insulae) of small, uniform carcinoma cells, small follicles containing thyroglobulin, frequent necrotic foci and variable mitotic activity. The tumor cells in ITC are derived from poorly differentiated follicular cells expressing thyroglobulin. The immunostaining of thyroglobulin differentiates ITC from other poorly differentiated thyroid tumors. In this case the immunohistochemical analysis was positive for thyroglobulin and negative for calcitonin, which confirmed that the tumor cells were follicular in origin 1 . ITC behaves differently compared with other thyroid carcinomas, with more frequent metastasis and lower average 20-year post-diagnosis survival. Our patient had other characteristics that conferred a poor prognosis, including advanced age, high rate of mitosis, and multiple metastases. Although surgery and radioactive iodine are first line, this patient's tumor extension required alternative therapies. Radiotherapy and lenvatinib, a tyrosine kinase receptor inhibitor, were employed unsuccessfully. 1. Soza, J., et al. Insular Thyroid Cancer. Cancer, 3260-3267. Presentation: No date and time listed
Styles APA, Harvard, Vancouver, ISO, etc.
2

Evans, Carol, Sarah Tennant et Petros Perros. « Thyroglobulin in differentiated thyroid cancer ». Clinica Chimica Acta 444 (avril 2015) : 310–17. http://dx.doi.org/10.1016/j.cca.2014.10.035.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Lin, Jen-Der. « Thyroglobulin and human thyroid cancer ». Clinica Chimica Acta 388, no 1-2 (février 2008) : 15–21. http://dx.doi.org/10.1016/j.cca.2007.11.002.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Xiao, Qian, Qiang Jia, Jian Tan et Zhaowei Meng. « Serum biomarkers for thyroid cancer ». Biomarkers in Medicine 14, no 9 (juin 2020) : 807–15. http://dx.doi.org/10.2217/bmm-2019-0578.

Texte intégral
Résumé :
The high prevalence of thyroid cancer requires a reliable serum biomarker for diagnosis and prognostic monitoring. Serum thyroglobulin has been established as the primary postoperative and postablative monitoring biomarker for this malignancy. However, the presence of thyroglobulin antibody imposes a significant interference on its overall management, which cannot be diminished by currently available assays. Trends on the level of the thyroglobulin antibody during follow-up is considered as a surrogate biomarker, but controversy exists. A variety of alternative biomarkers are being proposed and investigated, nevertheless, clinical trials and prospective validations are needed before they can be regarded as clinically viable serum parameters for thyroid cancer.
Styles APA, Harvard, Vancouver, ISO, etc.
5

Shulan, Joseph M., Leonid Vydro, Arthur B. Schneider et Dan V. Mihailescu. « Role of biomarkers in predicting the occurrence of thyroid neoplasms in radiation-exposed children ». Endocrine-Related Cancer 25, no 4 (avril 2018) : 481–91. http://dx.doi.org/10.1530/erc-17-0408.

Texte intégral
Résumé :
With increasing numbers of childhood cancer survivors who were treated with radiation, there is a need to evaluate potential biomarkers that could signal an increased risk of developing thyroid cancer. We aimed to examine the relationships between thyrotropin and thyroglobulin levels and the risk of developing thyroid nodules and cancer in a cohort of radiation-exposed children. 764 subjects who were irradiated in the neck area as children were examined and followed for up to 25 years. All subjects underwent a clinical examination, measurements of thyrotropin, thyroglobulin levels and thyroid imaging. At baseline, 216 subjects had thyroid nodules and 548 did not. Of those with nodules, 176 underwent surgery with 55 confirmed thyroid cancers. During the follow-up, 147 subjects developed thyroid nodules including 22 with thyroid cancer. Thyroglobulin levels were higher in subjects with prevalent thyroid nodules (26.1 ng/mL vs 9.37 ng/mL; P < 0.001) and in those who had an initial normal examination but later developed thyroid nodules (11.2 ng/mL vs 8.87 ng/mL; P = 0.017). There was no relationship between baseline thyrotropin levels and the prevalent presence or absence of thyroid nodules, whether a prevalent neoplasm was benign or malignant, subsequent development of thyroid nodules during follow-up or whether an incident nodule was benign or malignant. In conclusion, in radiation-exposed children, higher thyroglobulin levels indicated an increased risk of developing thyroid nodules but did not differentiate between benign and malignant neoplasms. There was no association between the baseline TSH level and the risk of developing thyroid nodules or cancer.
Styles APA, Harvard, Vancouver, ISO, etc.
6

Buyvalenko, U. V., A. R. Levshina et E. E. Sakhnova. « Alternative biomarkers of thyroid cancer ». Clinical and experimental thyroidology 18, no 1 (11 juillet 2022) : 21–28. http://dx.doi.org/10.14341/ket12715.

Texte intégral
Résumé :
Serum thyroglobulin is the main biomarker for postoperative monitoring of papillary thyroid cancer recurrence however, the high prevalence of the disease dictates the need to find a reliable indicator for laboratory diagnosis of the tumor process. The presence of antibodies to thyroglobulin affects the prognosis of the disease and determines the likelihood of relapse; however, it is impossible to influence the level of antibodies using currently available methods. More commonly, trends in anti-thyroglobulin levels at the time of disease detection and after radical treatment are considered, but there is disagreement on the interpretation of the results. Currently, various alternative biomarkers are being proposed and studied, the evaluation and comparison of which will be the subject of this literature review.
Styles APA, Harvard, Vancouver, ISO, etc.
7

Lin, Jen-Der, Hong-So Huang, Shin-Cheh Chen et Tzu-Chieh Chao. « Factors that Predict Metastasis of Papillary and Follicular Thyroid Cancers in Taiwan ». Otolaryngology–Head and Neck Surgery 116, no 4 (avril 1997) : 475–82. http://dx.doi.org/10.1016/s0194-59989770297-3.

Texte intégral
Résumé :
The purpose of this study is to explore the relationship of postoperative thyroglobulin level and other clinical factors with tumor metastasis. Analysis of 281 pathologic lesions verified patients with papillary and follicular thyroid cancer who received their primary treatment at Chang Gung Memorial Hospital. Clinical information—including postoperative thyroglobulin levels, age, sex, primary tumor size, clinical staging, surgical methods, surgical findings, chest x-ray findings, and 131I uptake—were stored in the computer. Actual survival rate and univariate and multivariate analyses of these factors with the relationship of distant metastases were undertaken. Twenty-three patients in this study died of distant metastases from the thyroid cancer. Of these patients, 30.4% were older than 60 years. In contrast only 8.5% of patients in the survival group were older than 60 years (p < 0.05 in χ 2 ). All of the papillary thyroid cancer patients with distant metastases displayed thyroglobulin levels higher than 25 ng/ml, but only 24% (41 of 173 cases) of those without distant metastases had thyroglobulin levels higher than 25 ng/ml. In 12 follicular thyroid cancer patients with distant metastases, 11 patients' serum thyroglobulin levels were higher than 25 ng/ml. In contrast, only 7 of 33 patients with follicular thyroid cancer without distant metastases displayed similar thyroglobulin levels. Univariate analysis revealed that age, postoperative thyroglobulin levels, chest x-ray findings, pathologic type, and tumor size are associated with distant metastases. One-month postoperative serum thyroglobulin level could be used as a prognostic factor for papillary and follicular thyroid cancer patients with distant metastases.
Styles APA, Harvard, Vancouver, ISO, etc.
8

Krahn, John, et Tom Dembinski. « Thyroglobulin and anti-thyroglobulin assays in thyroid cancer monitoring ». Clinical Biochemistry 42, no 4-5 (mars 2009) : 416–19. http://dx.doi.org/10.1016/j.clinbiochem.2008.12.017.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

Wang, Chih-Yuan, Wen-Bin Zhong, Tien-Chun Chang, Shu-Mei Lai et Yuan-Feen Tsai. « Lovastatin, a 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor, Induces Apoptosis and Differentiation in Human Anaplastic Thyroid Carcinoma Cells ». Journal of Clinical Endocrinology & ; Metabolism 88, no 7 (1 juillet 2003) : 3021–26. http://dx.doi.org/10.1210/jc.2002-021834.

Texte intégral
Résumé :
Although only 1% of differentiated thyroid cancers transform into anaplastic thyroid cancer, this disease is always fatal. Differentiation therapy may provide a new therapeutic approach to increasing the survival rate in such patients. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are reported to promote cellular apoptosis and differentiation in many cancer cells; these effects are unrelated to lipid reduction. Recently, we found that TNFα induces cytomorphological differentiation in anaplastic thyroid cancer cells and increases thyroglobulin expression; however, TNF is cytotoxic for normal human tissue. The aim of this study was to determine whether lovastatin, an HMG-CoA reductase inhibitor, could induce apoptosis and differentiation in anaplastic thyroid cancer cells. Anaplastic thyroid cancer cells were treated with lovastatin, then examined for cellular apoptosis and cytomorphological differentiation by DNA fragmentation, phosphatidylserine externalization/flow cytometry, and electron microscopy. Thyroglobulin levels in the culture medium were also measured. Our results showed that at a higher dose (50 μm), lovastatin induced apoptosis of anaplastic thyroid cancer cells, whereas at a lower dose (25 μm), it promoted 3-dimensional cytomorphological differentiation. It also induced increased secretion of thyroglobulin by anaplastic cancer cells. Our results show that lovastatin not only induces apoptosis, but also promotes redifferentiation in anaplastic thyroid cancer cells, and suggest that it and other HMG-CoA reductase inhibitors merit further investigation as differentiation therapy for the treatment of anaplastic thyroid cancer.
Styles APA, Harvard, Vancouver, ISO, etc.
10

Purizhansky, I. I., T. V. Ogneva, K. U. Kadyrov, Kh Yu Al-Sakhii et A. P. Alyoshkin. « Clinical assessment of the data of radionuclide studies in the diagnosis of malignant tumors of the thyroid ». Problems of Endocrinology 41, no 2 (15 avril 1995) : 17–19. http://dx.doi.org/10.14341/probl11365.

Texte intégral
Résumé :
A total of 386 patients with nodular goiter, compensated adenoma, lymphocytic thyroiditis, relapses of thyroid cancer, and metastases of thyroid cancer to regional lymph nodes were examined in order to assess the informative value of in vivo and in vitro radionuclide studies. In vivo studies were carried out using different systems of visual information processing gamma-chamber with 99mTc - pertechnetate, sodium iodide (131I, 123I) and 201Т1-chloride. Standard radioimmunoassay kits were used for measurements of blood serum levels of thyroxin, triiodothyronine, hypophyseal thyroid hormone, thyroglobulin and antibodies to it, parathyroid hormone, and calcitonin. 201Т1-chloride was found to be the optimal radionuclide for the differential diagnosis of tumors of the thyroid; as for the most informative in vitro test, thyroglobulin measurements should be preferred.
Styles APA, Harvard, Vancouver, ISO, etc.
Plus de sources

Thèses sur le sujet "Thyroid cancer, Thyroglobulin"

1

Leire, Christophe. « Surveillance évolutive des cancers différenciés du corps thyroi͏̈de : valeur comparée de la détermination de la thyroglobuline plasmatique et de la scintigraphie toto corporelle à l'131 I /par Christophe Leire ». Montpellier 1, 1989. http://www.theses.fr/1989MON11097.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

LIGEARD, DUCOROY ANNE. « Diagnostic des metastases dans les carcinomes thyroidiens differencies : comparaison scintigraphie corporelle a l'iode 131 et dosage de thyroglobuline ». Angers, 1992. http://www.theses.fr/1992ANGE1004.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

TOLINI, SIMONNE. « Interet de l'association du dosage de la thyroglobuline au controle de la fixation a l'iode 131 apres thyroidectomie totale pour cancer differencie de la thyroide : a propos de 158 patients ». Aix-Marseille 2, 1988. http://www.theses.fr/1988AIX20349.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Druetta, Laure. « Identification et caractérisation des formes moléculaires de la thyroglobuline sérique chez l'homme : études sur le sérum de patients atteints de maladie de Basedow, de cancer différencié de la thyroïde ou de thyroïdite subaiguë ». Lyon 1, 1998. http://www.theses.fr/1998LYO1T144.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

MANCINI, IRENE. « Sviluppo e validazione di metodiche per l’analisi molecolare nella diagnostica dei noduli tiroidei ». Doctoral thesis, 2014. http://hdl.handle.net/2158/850910.

Texte intégral
Résumé :
Tesi di Dottorato. L’attività di ricerca svolta ha avuto come obiettivo principale la ottimizzazione di un protocollo per l’analisi molecolare dei marcatori tumorali descritti in letteratura nel contesto dei carcinomi differenziati della tiroide. Il lavoro nasce in risposta alla volontà di introdurre l’indagine molecolare nel percorso assistenziale previsto per i pazienti affetti da patologia nodulare della tiroide, afferenti all’ambulatorio dell’Unità di Endocrinologia dell’Azienda Ospedaliera Careggi. La ricerca si è, quindi, sviluppata nello studio delle mutazioni a carico dei geni BRAF, KRAS, NRAS, HRAS e dei riarrangiamenti RET/PTC1, RET/PTC3 e PAX8/PPARγ che rappresentano le alterazioni, secondo la letteratura in materia, più frequenti nella carcinogenesi delle cellule follicolari tiroidee. I principali aspetti considerati per la selezione dell’approccio metodologico sono stati: l’impiego di tecniche già consolidate presso il laboratorio dell’Unità di Biochimica Clinica del Dipartimento di Scienze Biomediche, Sperimentali e Cliniche; l’allestimento di saggi molecolari da eseguire in parallelo e con tempi di esecuzione e risposta sufficientemente rapidi oltre che sensibili e specifici; l’impiego di un campione biologico di semplice reperibilità per la collezione del quale non si rendesse necessario alcun aumento di invasività per i pazienti. Al fine di esplorare il significato dei risultati forniti dall’indagine molecolare è stata, inoltre, fondamentale la raccolta di informazioni cliniche e del dato citologico e istologico relativo ai noduli analizzati. Lo studio riporta i risultati ottenuti dall’analisi molecolare di una casistica complessiva di 430 campioni di materiale citologico da noduli tiroidei di pazienti sottoposti a agobiopsia presso l’Unità di Endocrinologia. Per la valutazione iniziale dei metodi previsti nello studio è stata analizzata una casistica iniziale composta da 100 campioni per 45 dei quali era disponibile sia un campione citologico vero e proprio, derivante da una seconda biopsia a livello dello stesso nodulo, sia il lavaggio del materiale residuo del primo agoaspirato inviato all’analisi citologica. Lo studio di validazione del metodo ha dimostrato, mediante l’impiego di saggi di PCR real time per geni di controllo (GAPDH, Tireoglobulina, BRAF), la possibilità di impiego non soltanto del materiale citologico vero e proprio per l’analisi molecolare ma anche del campione di lavaggio. Soltanto 25 campioni su un totale 430 lavaggi analizzati si sono, infatti, rivelati non idonei per l’analisi molecolare. L’analisi High Resolution Melting, scelta come metodo di pre-screening, dei prodotti di amplificazione, ottenuti mediante la amplificazione con primer specifici per le regioni di interesse, ha mostrato le caratteristiche desiderate sia in termini di sensibilità che di specificità per la selezione dei campioni positivi. Grazie all’approccio metodologico impiegato, sono stati individuati 77 campioni positivi per la presenza di una alterazione genetica con una distribuzione diversa nelle categorie diagnostiche della citologia: 7/56 campioni in classe Tir1 (inadeguati), 10/184 in classe Tir2 (benigni), 33/155 in Tir3 (proliferazioni follicolari di incerto significato), 12/19 in Tir4 (sospetti), 15/16 in Tir5 (carcinomi). In particolare, l’analisi delle alterazioni genetiche ha confermato che la mutazione riscontrata con maggior frequenza nel contesto dei carcinomi differenziati della tiroide è rappresentata dalla p.V600E nel gene BRAF. Il dato risulta coerente con la incidenza nettamente superiore di carcinomi papillari, rispetto alle altre varianti di carcinoma differenziato, per i quali sembra essere un marcatore estremamente specifico. Per 91 noduli appartenenti alla casistica analizzata è stato, inoltre, possibile effettuare un confronto tra il genotipo identificato nel campione citologico e l’esito dell’esame istologico. La presenza della mutazione BRAF p.V600E è stata individuata in 14 su 22 campioni con diagnosi di carcinoma papillare. Sono stati, inoltre, individuati 6 campioni positivi per la stessa mutazione in campioni classificati come lesioni di natura benigna durante la analisi citologica. Soltanto per uno di questi noduli si è reso disponibile l’esito dell’esame istologico il quale ha fornito un risultato concorde con l’analisi molecolare, contribuendo ad avvalorare il valore predittivo positivo del marcatore. Analogamente, la presenza di un riarrangiamento cromosomico RET/PTC, ha mostrato un potente significato diagnostico. Tre campioni portatori del riarrangiamento RET/PTC1 sono stati confermati all’esame istologico carcinomi papillari della tiroide. Nessun campione ha mostrato la presenza di riarrangiamenti PAX8/PPARγ, motivo per il quale potrà essere considerata la rimozione di tale marcatore dal pannello in esame e la sostituzione con nuovi marcatori. Infine, l’analisi di mutazioni a carico delle isoforme di RAS ha portato alla identificazione di una variante di sequenza in otto campioni che all’esame istologico sono risultati negativi mentre soltanto per quattro campioni mutati in uno dei geni RAS è stata confermata la presenza di una neoplasia. Questo ha portato a considerare RAS come un marcatore meno specifico di malignità in quanto frequentemente riscontrato anche a livello di adenomi follicolari. Importante sarà comprendere se mutazioni a carico di questi geni insorgano in fasi estremamente precoci del processo di trasformazione neoplastica e possano determinare l’evoluzione del nodulo verso un fenotipo maligno. Inoltre, risulterà interessante investigare il significato biologico della identificazione di quattro campioni portatori contemporaneamente della mutazione BRAF p.V600E e di una mutazione a livello dei geni RAS. I risultati ottenuti hanno, infine, permesso di valutare la sensibilità e la specificità raggiunti dalla indagine molecolare comparando il risultato con il dato istologico. L’impiego dell’intero pannello di marcatori oggetto di studio ha mostrato una sensibilità del 70% e una specificità dell’81%. Il calcolo dei valori ottenuti considerando singolarmente ogni tipo di alterazione ha permesso di confermare che il maggior contributo alla significatività diagnostica del test è fornito dallo studio dello stato mutazionale del gene BRAF. Resta comunque aperta la possibilità di rivalutare nel corso del tempo l’effetto apportato dagli altri geni, in seguito alla acquisizione di nuove informazioni clinicopatologiche, e l’incremento della accuratezza diagnostica mediante la eventuale introduzione di nuovi marcatori.
Styles APA, Harvard, Vancouver, ISO, etc.

Chapitres de livres sur le sujet "Thyroid cancer, Thyroglobulin"

1

Dufour, D. Robert. « Thyroglobulin and Thyroglobulin Antibodies ». Dans Thyroid Cancer, 297–304. Totowa, NJ : Humana Press, 2006. http://dx.doi.org/10.1007/978-1-59259-995-0_30.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Fatemi, Shireen, et Carole Spencer. « Thyroglobulin ». Dans Practical Management of Thyroid Cancer, 155–86. Cham : Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-91725-2_15.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Dufour, D. Robert. « Thyroglobulin Antibodies and Their Measurement ». Dans Thyroid Cancer, 443–47. New York, NY : Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3314-3_38.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Dufour, D. Robert. « Thyroglobulin in Lymph Node Aspirate ». Dans Thyroid Cancer, 525–28. New York, NY : Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3314-3_46.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Dufour, D. Robert. « Thyroglobulin for Differentiated Thyroid Cancer : Measurement and Interferences ». Dans Thyroid Cancer, 433–42. New York, NY : Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3314-3_37.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Ringel, Matthew D., et Jennifer A. Sipos. « Diagnosis of Recurrent Thyroid Cancer in Patients with Anti-thyroglobulin Antibodies ». Dans Thyroid Cancer, 449–54. New York, NY : Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3314-3_39.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Wartofsky, Leonard. « Management of the Patients with Negative Radioiodine Scan and Elevated Serum Thyroglobulin ». Dans Thyroid Cancer, 367–74. Totowa, NJ : Humana Press, 2006. http://dx.doi.org/10.1007/978-1-59259-995-0_41.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Wartofsky, Leonard. « Management of the Patients with Negative Radioiodine Scan and Elevated Serum Thyroglobulin ». Dans Thyroid Cancer, 529–38. New York, NY : Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3314-3_47.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

Lamartina, Livia, Sebastiano Filetti et Cosimo Durante. « A Young Patient with Recurrent Lymph Node Involvement : Imaging, Cytology, and Thyroglobulin Washout ». Dans Thyroid Cancer, 145–51. Cham : Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-22401-5_16.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

Ramundo, Valeria, Sebastiano Filetti et Cosimo Durante. « A Young Patient with Recurrent Lymph Node Involvement : Imaging, Cytology, and Thyroglobulin Washout ». Dans Thyroid Cancer, 131–38. Cham : Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-61919-0_15.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "Thyroid cancer, Thyroglobulin"

1

Raki, Logesh, Rehena Ganguly et Joanne Ngeow. « Abstract 3468 : Impact of histology on serum thyroglobulin as a biomarker for nonmedullary thyroid cancer recurrence ». Dans Proceedings : AACR 106th Annual Meeting 2015 ; April 18-22, 2015 ; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-3468.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Quero, G., R. Severino, P. Vaiano, M. Consales, M. Ruvo, A. Sandomenico, A. Borriello et al. « High sensitive reflection type long period fiber grating biosensor for real time detection of thyroglobulin, a differentiated thyroid cancer biomarker : the Smart Health project ». Dans International Conference on Optical Fibre Sensors (OFS24), sous la direction de Hypolito J. Kalinowski, José Luís Fabris et Wojtek J. Bock. SPIE, 2015. http://dx.doi.org/10.1117/12.2194916.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Vous pouvez également être intéressé par les bibliographies sur le sujet « Thyroid cancer, Thyroglobulin » pour d’autres types de sources :
Articles de revues
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!

Vers la bibliographie